Venture Capital Investors

Aisling Capital

Aisling Capital makes VC investments in high-tech companies.

Venture Investor Overview

Venture Investor
Aisling Capital
Status
Active
Investor Type
Venture Capital
Activity Level
97 transactions
Funds Raised
At least $1.5 billion
Industry Focus
Biopharmaceutical

Contact Information

Contact
Andrew Schiff
Title
Managing Partner
Mailing Address
888 Seventh Ave. 12th Floor
New York, NY 10106
USA
Phone
(212) 651-6380
Website
www.aislingcapital.com
Email Address
Not Recorded

Background Information

Overview
The firm seeks promising companies in the biotechnology, pharmaceutical and other suitable life science companies and typically makes investments of $15 - $30 million over the life of the company.
Profile
Aisling Capital LinkedIn Company Profile
Social Media
Aisling Capital Company Twitter Account
Company News
Aisling Capital News
Facebook
Aisling Capital on Facebook
YouTube
Aisling Capital on YouTube
Last Transaction
12/12/2023

Transaction History

Our records indicate that Aisling Capital invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Bicara Therapeutics
12/12/2023
$165,000,000
COMPASS Pathways
8/18/2023
$285,000,000
Garuda Therapeutics
2/7/2023
$62,000,000
Forge Biologics
9/12/2022
$90,000,000
Dren Bio
6/14/2022
$65,000,000
Antios Therapeutics
11/6/2021
$75,000,000
Garuda Therapeutics
9/24/2021
$72,000,000
Antios Therapeutics
4/13/2021
$96,000,000
Monte Rosa Therapeutics
3/15/2021
$95,000,000
Biomea Fusion
1/7/2021
$56,000,000
Reneo Pharmaceuticals
12/10/2020
$95,000,000
Elevation Oncology
11/19/2020
$65,000,000
Talaris Therapeutics
10/7/2020
$115,000,000
Monte Rosa Therapeutics
9/25/2020
$96,000,000
Elevation Oncology
7/22/2020
$32,500,000
Spruce Biosciences
2/21/2020
$88,000,000
Nuvation Bio
10/30/2019
$275,000,000
Poseida Therapeutics
4/23/2019
$142,000,000
Ajax Health
4/15/2019
$85,000,000
BridgeBio Pharma
1/24/2019
$299,200,000
Atreca
9/13/2018
$125,000,000
Ajax Health
7/11/2018
$120,000,000
Eidos Therapeutics
4/6/2018
$64,000,000
Avrobio
2/2/2018
$60,000,000
Arcus Biosciences
11/14/2017
$107,000,000
BridgeBio Pharma
9/14/2017
$135,000,000
Menlo Therapeutics
7/19/2017
$50,000,000
Earlens
5/26/2017
$118,000,000
Promentis Pharmaceuticals
3/31/2017
$26,000,000
Biohaven Pharmaceuticals
11/2/2016
$80,000,000
F2G
6/21/2016
$60,000,000
Earlens
3/31/2016
$53,593,200
PowerVision
3/31/2016
$10,000,000
Zavante Therapeutics
3/30/2016
$45,000,000
Spirox
3/15/2016
$45,000,000
Syros Pharmaceuticals
1/13/2016
$40,000,000
Spirox
4/22/2015
$18,500,000
Allergen Research
3/12/2015
$80,000,000
Seachaid Pharmaceuticals
12/31/2014
$100,000
Dermira
8/19/2014
$51,000,000
Seachaid Pharmaceuticals
6/30/2014
$3,230,000
Cidara Therapeutics
6/30/2014
$32,000,000
PowerVision
6/17/2014
$10,000,000
Loxo Oncology
5/6/2014
$24,000,000
Earlens
3/31/2014
$36,258,000
Paratek Pharmaceuticals
3/31/2014
$662,000
Versartis
2/18/2014
$55,000,000
Miramar Labs
2/13/2014
$10,000,000
ViewRay
12/17/2013
$30,000,000
Seragon Pharmaceuticals
10/18/2013
$30,000,000
Versartis
10/8/2013
$20,000,000
Loxo Oncology
10/4/2013
$33,000,000
LensAR
10/3/2013
$27,000,000
Seachaid Pharmaceuticals
9/30/2013
$500,000
Esperion Therapeutics
4/25/2013
$33,000,000
T2 Biosystems
3/28/2013
$40,000,000
Versartis
1/15/2013
$25,000,000
TRIA Beauty
12/31/2012
$7,501,200
Ambit Biosciences
11/6/2012
$50,000,000
Aragon Pharmaceuticals
9/26/2012
$49,999,988
ViewRay
3/13/2012
$45,000,000
LensAR
3/12/2012
$24,000,000
Aragon Pharmaceuticals
3/6/2012
$42,000,000
Roka Bioscience
1/9/2012
$47,500,000
TRIA Beauty
12/31/2011
$20,000,000
Advion
12/31/2011
$5,001,000
T2 Biosystems
8/10/2011
$23,000,000
TRIA Beauty
4/20/2011
$21,000,000
TRIA Beauty
9/13/2010
$15,600,000
ViewRay
8/25/2010
$20,000,000
Cempra
6/30/2010
$20,499,900
CoolSculpting
6/2/2010
$25,000,000
Aragon Pharmaceuticals
4/23/2010
$22,000,000
Diroda Therapeutics
12/31/2009
$3,000,000
TransEnterix
10/7/2009
$55,000,000
CeNeRx BioPharma
6/16/2009
$9,000,000
Xanodyne Pharmaceuticals
6/4/2009
$38,000,000
Cempra
5/14/2009
$46,000,000
CeNeRx BioPharma
10/17/2008
$15,000,000
HDL Therapeutics
6/30/2008
$10,250,000
Esperion Therapeutics
5/1/2008
$22,750,000
Paratek Pharmaceuticals
4/16/2008
$18,000,000
ViewRay
1/22/2008
$25,000,000
Cempra
1/14/2008
$10,000,000
Topaz Pharmaceuticals
12/4/2007
$20,000,000
Paratek Pharmaceuticals
10/25/2007
$22,000,000
Advion
9/30/2007
$9,114,100
Xanodyne Pharmaceuticals
7/27/2007
$25,000,000
Dynova Laboratories
6/30/2007
$3,000,000
BioRelix
6/4/2007
$25,750,000
The Natural Dentist
4/25/2007
$13,000,000
Sirion Therapeutics
4/9/2007
$45,000,000
Cempra
9/30/2006
$14,000,000
ARMGOPharma
6/30/2006
$3,500,000
CeNeRx BioPharma
6/30/2006
$1,600,000
ArgiNOx Pharmaceuticals
6/30/2006
$1,100,000
Avera Pharmaceuticals
3/31/2005
$18,000,200

 

Investor Contacts

Title
Name
Email & Social
Partner
Eric Aguiar
  Eric Aguiar LinkedIn Profile  Eric Aguiar Twitter Account  Eric Aguiar News  Eric Aguiar on Facebook
Managing Partner
Steven Elms
  Steven Elms LinkedIn Profile  Steven Elms Twitter Account  Steven Elms News  Steven Elms on Facebook
Partner
Aftab Kherani
  Aftab Kherani LinkedIn Profile  Aftab Kherani Twitter Account  Aftab Kherani News  Aftab Kherani on Facebook
Founder
Dennis Purcell
  Dennis Purcell LinkedIn Profile  Dennis Purcell Twitter Account  Dennis Purcell News  Dennis Purcell on Facebook
Managing Partner
Andrew Schiff
  Andrew Schiff LinkedIn Profile  Andrew Schiff Twitter Account  Andrew Schiff News  Andrew Schiff on Facebook
Partner
Stacey Seltzer
  Stacey Seltzer LinkedIn Profile  Stacey Seltzer Twitter Account  Stacey Seltzer News  Stacey Seltzer on Facebook

 

Funds

Our database includes the following fund closing(s) for Aisling Capital. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Aisling Capital V
6/27/2020
$144,154,915
Aisling Capital IV
11/2/2017
$280,000,000
Aisling Capital III
1/8/2009
$650,000,000
Aisling Capital II
1/6/2006
$472,500,000

 

Portfolio Companies

Aisling Capital has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Advion
Ajax Health
Allergen Research
Ambit Biosciences
Antios Therapeutics
Aragon Pharmaceuticals
Arcus Biosciences
ArgiNOx Pharmaceuticals
ARMGOPharma
Atreca
Avera Pharmaceuticals
Avrobio
Bicara Therapeutics
Biohaven Pharmaceuticals
Biomea Fusion
BioRelix
BridgeBio Pharma
Cempra
CeNeRx BioPharma
Cidara Therapeutics
COMPASS Pathways
CoolSculpting
Dermira
Diroda Therapeutics
Dren Bio
Dynova Laboratories
Earlens
Eidos Therapeutics
Elevation Oncology
Esperion Therapeutics
F2G
Forge Biologics
Garuda Therapeutics
HDL Therapeutics
LensAR
Loxo Oncology
Menlo Therapeutics
Miramar Labs
Monte Rosa Therapeutics
Nuvation Bio
Paratek Pharmaceuticals
Poseida Therapeutics
PowerVision
Promentis Pharmaceuticals
Reneo Pharmaceuticals
Roka Bioscience
Seachaid Pharmaceuticals
Seragon Pharmaceuticals
Sirion Therapeutics
Spirox
Spruce Biosciences
Syros Pharmaceuticals
T2 Biosystems
Talaris Therapeutics
The Natural Dentist
Topaz Pharmaceuticals
TransEnterix
TRIA Beauty
Versartis
ViewRay
Xanodyne Pharmaceuticals
Zavante Therapeutics

 

 

 

 

Browse more venture capital investors:

Airwing Ventures | AiSprouts VC

 

Share this article

 

About Our Venture Capital Investor Database

The venture capital investor data above is provided by VentureDeal.com, a market leader in private equity transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.